Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

94.4%

+7.9% vs industry average

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

6(35.3%)

N/A

5(29.4%)

Phase 1

4(23.5%)

Phase 3

2(11.8%)

17Total

Phase 2(6)

N/A(5)

Phase 1(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT06034379Not ApplicableRecruiting

Electronic Spectacles Versus Low Dose Atropine in Young Myopes

Role: lead

NCT06085430Not ApplicableCompleted

Kubota Glass Parameter Refinement Study

Role: lead

NCT03772665Phase 3Completed

Safety and Efficacy of Emixustat in Stargardt Disease

Role: lead

NCT05425108Not ApplicableUnknown

Binocular Peripheral Myopic Defocus Using a Clinical Prototype Device

Role: lead

NCT04415684Not ApplicableCompleted

Projected Peripheral Defocus Using a Wearable Device

Role: lead

NCT04388020Not ApplicableCompleted

Effects of Projected Peripheral Defocus on Ocular Biometrics

Role: lead

NCT02753400Phase 2Completed

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Role: lead

NCT03033108Phase 2Completed

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Role: lead

NCT04428242Withdrawn

Study Evaluating Retinal Health Monitoring System Thickness Module

Role: lead

NCT04169802Completed

Study Evaluating Retinal Health Monitoring System Visual Acuity Module.

Role: lead

NCT04499703Completed

Evaluation of the Retinal Health Monitoring System Thickness Module

Role: lead

NCT01802866Phase 2Completed

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

Role: lead

NCT02130531Phase 1Completed

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Role: lead

NCT01632137Phase 3Completed

Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome

Role: lead

NCT01410188Phase 1Completed

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT01002950Phase 2Completed

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Role: lead

NCT00703183Phase 1Completed

Safety and Tolerability of ACU-4429

Role: lead

NCT01057147Phase 2Completed

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

Role: lead

NCT01027013Phase 2Completed

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

Role: lead

NCT00942240Phase 1Completed

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

Role: lead

All 20 trials loaded